Mark Stejbach, Director at Flexion Therapeutics Inc (FLXN), bought 2,051 shares at $9.75 ($20K) on 2020-05-26, disclosed to the SEC on 2020-05-27.
Open-market purchase of $20k FLXN by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| FLXN | BUY | 2017-06-20 | $27K | — | Filing → |
| ALKS | SELL | 2017-06-08 | $603K | — | Filing → |
| ALKS | SELL | 2017-01-10 | $33K | — | Filing → |